Want to join the conversation?
$AMGN and Servier announced the omecamtiv mecarbil Phase 3 development program will move forward in collaboration with Cytokinetics. Servier will make a $10MM option exercise payment, as well as future milestone and royalty payments, to $AMGN. Servier will assume a share of the development costs.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.